CD96 deficiency reduced the frequencies of NUR77-, T-bet-, TNFα- and IFNγ-expressing tumor-specific CD8+ T cells in a mouse model of colorectal carcinoma, suggesting CD96 co-stimulated rather than inhibited effector T cell anti-tumor responses [15]. This evidence concerns the gene NR4A1 and neoplasm.